Final Analysis of COVID-19 Patients With Inflammatory Bowel Disease in Japan (J-COSMOS): A Multicenter Registry Cohort Study

Keyphrases

• Anti-tumor Necrosis Factor Antibody 9%
• Cerebrovascular Disease 9%
• Classification Treatment 9%
• Clinical Course 9%
• Clinical Remission 9%
• Conductor-like Screening Model for Real Solvents (COSMO-RS) 100%
• Coronavirus Disease 2019 Outbreak 9%
• Coronavirus Impact 9%
• Corticosteroids 9%
• COVID-19 100%
• Critical Disease 9%
• Disease Activity 27%
• Disease Classification 9%
• Disease Factor 9%
• Disease Severity 9%
• Disease Treatment 9%
• High Body Mass Index 9%
• Inflammatory Bowel Disease 100%
• Japan 100%
• Japanese Patients 9%
• Multicenter Registry 100%
• Non-severe 9%
• Number of Deaths 9%
• Observational Cohort Study 9%
• Risk Factors 9%
• Risk Reduction 9%
• Severe Coronavirus Disease 2019 18%
• Severe Disease 9%
• Severe Infection 9%
• Stepwise Logistic Regression Analysis 9%
• Symptom Severity 9%
• Thiopurines 9%
• World Health Organization Classification 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Cerebrovascular Disease 6%
• Cohort Study 100%
• Combination Therapy 6%
• Coronavirinae 100%
• Disease Activity 18%
• Disease Classification 6%
• Disease Course 6%
• Disease Severity 6%
• Diseases 100%
• Infection 6%
• Inflammatory Bowel Disease 100%
• Mercaptopurine 6%
• Remission 6%
• Tumor Necrosis Factor Antibody 6%

Medicine and Dentistry

• Inflammatory Bowel Disease 35%